| Identification | Back Directory | [Name]
Ripasudil | [CAS]
223645-67-8 | [Synonyms]
CS-1564
Ripasudil
k115 free base
K-115, Ripasudil
RIPASUDIL HYDROCHLOIDE
RIPASUDIL FREE BASE;K 115 FREE BASE;K115 FREE BASE
4-Fluoro-5-[[(2S)-hexahydro-2-methyl-1H-1,4-diazepin-1-yl]sulfonyl]isoquinoline
Isoquinoline, 4-fluoro-5-[[(2S)-hexahydro-2-methyl-1H-1,4-diazepin-1-yl]sulfonyl]- | [Molecular Formula]
C15H18FN3O2S | [MDL Number]
MFCD28291829 | [MOL File]
223645-67-8.mol | [Molecular Weight]
323.39 |
| Chemical Properties | Back Directory | [Description]
Ripasudil (Glanatec TM, Kowa Pharmaceutical), a close derivative of fasudil, is another Rho kinase inhibitor approved in Japan at the end of 2014 for the treatment of glaucoma and ocular hypertensionwhen other therapeutic agents are not effective or cannot be administered. Additionally, ripasudil has been tested in diabetic retinopathy clinical trials and shown to promote corneal endothelial cell proliferation, endothelium regeneration, and wound healing. | [Boiling point ]
497.2±55.0 °C(Predicted) | [density ]
1.293±0.06 g/cm3(Predicted) | [storage temp. ]
under inert gas (nitrogen or Argon) at 2–8 °C | [pka]
9.70±0.40(Predicted) |
|
| Company Name: |
Flax Laboratories
|
| Tel: |
+91-9867665132 +91-9867665132 |
| Website: |
www.flaxlaboratories.com |
|